About Event
Learn More About the Longevity Therapeutics Summit
As the FDA continues to deny aging as an indication with a lack of robust surrogate biomarkers for aging and the high cost of running trials that measure lifespan in humans, now is the time for leaders in the longevity community to unite and tackle the field’s toughest challenges.
The Longevity Therapeutics Summit is your one-stop forum to fast-track the development of anti-aging drugs aiming to enhance the healthspan, whilst uncovering the key R&D challenges limiting the development of these therapies.
Join 100+ pioneers from Deep Longevity, Insilico Medicine, Elevian and Rubedo Life Sciences and deep-dive into presentations covering cellular senescence, telomere attrition, loss of proteostasis, stem cell exhaustion, stem cell, mitochondria, and more.
Here's What Topics You Missed:
- The rise in and efficacy of senolytics and senotherapeutics entering the clinic
- Accelerating the conversion of biomarkers into registrable endpoints
- Utilizing epigenetic reprogramming
- Advancements in AI drug discovery platforms
- Demonstrating clinical significance in age-related diseases and aging as a disease
- Navigating funding challenges within a lucrative market
Unmissable Sessions to Address Your Key Challenges Inlcuded:
Interested in accelerating your biomarkers into registrable endpoints? Expert discussions addressed how to advance the conversion of biological clocks and other biomarkers of aging into surrogate markers or registrable endpoints for regulatory development
Senotherapeutics and senolytics - the future of longevity, or the past? Our KOLs debated by revealing recent data on destroying senescent cells to treat age-related diseases
Want to invest in longevity? We unapcked how venture capitalists are investing in longevity, translating, and commercializing regenerative medicine
We welcomed Leucadia Therapeutics, Deep Longevity Limited, Fountain Therapeutics and The Furman Lab & Buck AI Platform to learn how they are using multi-omics, big data, deep learning, machine learning, and AI to understand the complexity of aging as an indication
Keen to progress towards the clinic? We hosted exclusive case studies on successful clinical and preclinical trials and gave actionable insights to help accelerate your pipeline to the clinic
